HCM ▼ -0.9% - HUTCHMED (China) Limited $HCM - HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China HCM shares fell 0.9% despite the company announcing positive SANOVO trial results showing that ORPATHYS® combined with TAGRISSO® delivered significant progression-free survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China. The trial data represents a potential advancement for the company's oncology pipeline, though investors may be digesting the results cautiously or the market may have already priced in expectations for this update. 30-AUG-2026 08:00 PM ET